QIAGEN fully acquires NeuMoDx Molecular

QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million

18-Sep-2020 - QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after ...

QIAGEN acquires Spanish diagnostics start-up company

QIAGEN enters into agreement to acquire STAT-Dx

09-Feb-2018 - QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...

QIAGEN and Biotype Diagnostics form partnership

30-Jun-2015 - QIAGEN and Biotype Diagnostics GmbH announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation"). The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s ...

QIAGEN Expands Partnership with Genome Diagnostics for Development of Tests in Prevention and Personalized Healthcare

Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases

21-Jun-2010 - QIAGEN announced that it has entered into an agreement with the Dutch molecular diagnostic component supplier Genome Diagnostics which covers the development and commercialization of 6 new tests until 2011. QIAGEN believes that this collaboration will further expand the Company’s testing ...

QIAGEN Acquires DxS Ltd

24-Sep-2009 - QIAGEN N.V. announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The transaction is valued at approximately US$ 95 million in cash (subject to customary purchase price adjustments), ...

EU Launches Project to Improve In-Vitro Diagnostics

QIAGEN led-consortium to develop standards for patient sample processing in order to facilitate the discovery and prediction of diseases

14-Jan-2009 - The European Union launched a new research project targeting to expand the potentials and utility of in-vitro diagnostics through the creation of new standards for the collection, handling and processing of blood, tissue, tumor and other sample materials. Under the 7th Framework Programme, the ...

OncoMethylome Sciences licenses methylation technologies to Qiagen for commercializing epigenetic applications

14-Nov-2008 - OncoMethylome Sciences announced that it has signed a world-wide, non-exclusive license agreement with QIAGEN. Under this agreement, QIAGEN has licensed certain of OncoMethylome's methylation technologies for use in certain of QIAGEN's future products. These products will expand, among others, ...

QIAGEN Acquires Biosystems Business from Biotage

Transaction adds fundamental assay technology for high-resolution sequence detection and quantification of genetic variations

06-Oct-2008 - QIAGEN N.V. announced that it has acquired all assets related to the Biosystems business from Biotage AB, a publicly listed developer, manufacturer and distributor of products for genetic analysis and medicinal chemistry headquartered in Uppsala, Sweden. The transaction is valued at approximately ...

Singapore's first commercial developer of molecular diagnostic assays commences operation

11-Sep-2008 - Dx Assays Pte Ltd, announced that it has officially started its operations. The company was established end 2007, as a joint venture between QIAGEN and Bio*One Capital. Dx Assays was formally launched at an opening ceremony attended by some 50 guests. Dx Assays will develop and validate ...

QIAGEN and BioHelix Enter Into Licensing Agreement

Helicase-dependent isothermal DNA amplification system provides new assay technology capabilities for QIAGEN's assay automation platforms

05-May-2008 - QIAGEN and privately held BioHelix have announced that they have entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helicase Dependent Amplification technology (HDA). HDA is a versatile assay technology to detect and analyze biological target molecules ...